Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Non-cash Items (2018 - 2025)

Aytu Biopharma (AYTU) has disclosed Non-cash Items for 8 consecutive years, with $138042.0 as the latest value for Q4 2025.

  • On a quarterly basis, Non-cash Items rose 69.59% to $138042.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $138042.0, a 69.59% increase, with the full-year FY2025 number at $100195.0, up 299.69% from a year prior.
  • Non-cash Items was $138042.0 for Q4 2025 at Aytu Biopharma, up from $103898.0 in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $300000.0 in Q3 2023 to a low of $2664.0 in Q4 2022.
  • A 5-year average of $88827.6 and a median of $63059.0 in 2024 define the central range for Non-cash Items.
  • Biggest YoY gain for Non-cash Items was 668.39% in 2023; the steepest drop was 98.54% in 2023.
  • Aytu Biopharma's Non-cash Items stood at $47838.0 in 2021, then tumbled by 94.43% to $2664.0 in 2022, then soared by 668.39% to $20470.0 in 2023, then soared by 297.65% to $81399.0 in 2024, then surged by 69.59% to $138042.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Non-cash Items are $138042.0 (Q4 2025), $103898.0 (Q3 2025), and $100195.0 (Q2 2025).